Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 1/20 | 0.58 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169237 | 0.85 | PRKD1 (0.43) | MELKPRKD1NPC1RAB9AFLT3 | |
| SCHEMBL12091914 | 0.82 | NPC1 (0.67) | MELKNPC1RAB9AFLT3KDR | |
| SCHEMBL12077090 | 0.80 | FLT3 (0.71) | MELKNPC1RAB9AFLT3KDR | |
| SCHEMBL7000736 | 0.78 | MELK (0.54) | MELKPRKD1NPC1RAB9AFLT3 | |
| SCHEMBL12077933 | 0.77 | FLT3 (0.72) | PRKD1NPC1RAB9AFLT3KDR | |
| SCHEMBL12077116 | 0.77 | FLT3 (0.73) | NPC1RAB9AFLT3KDRAURKA | |
| SCHEMBL12094305 | 0.76 | FLT3 (0.71) | PRKD1NPC1RAB9AFLT3KDR | |
| SCHEMBL12077607 | 0.75 | FLT3 (0.75) | NPC1RAB9AFLT3KDRAURKA | |
| SCHEMBL12091913 | 0.75 | FLT3 (0.55) | PRKD1NPC1RAB9AFLT3KDR | |
| SCHEMBL12077708 | 0.75 | FLT3 (0.74) | NPC1RAB9AFLT3KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566363-B2 | 5-amino-3-substituted-pyrazolo(4,5-d)thiazole compounds that mediate and/or inhibit the activity of cyclin-dependent kinases, useful for treating cancer, angiogenesis and cellular proliferation | AGOURON PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | AGOURON PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049215-A1 | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | CDK4, CCNK, CDK2 | MELK 183/4885PRKD1 317/4885NPC1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.